Navigation Links
Anti-smoking Drug Could Help Treat Alcoholism: Study

A recently approved anti-smoking medication could also serve to repress an alcoholic's desire for drink, according to a new study by researchers at the University of California-San Francisco .

Varenicline, manufactured by Pfizer and approved as a smoking cessation aid in the United States and Europe in 2006, has been shown to reduce nicotine consumption by affecting the brain's reward system for addictive substances.

The research team, noting that cigarettes and alcohol are often abused together, wanted to see if the drug had the same affect on drinking.

The researchers tested the impact of varenicline -- know by its trade names Chantix in the United States and Champix in Europe -- on laboratory rats which had consumed high amounts of ethanol over a long period.

Rats were trained to drink ethanol in consistent amounts over five months before they were given varenicline. After the drug was administered steadily, the rats consistently showed less interest in the ethanol.

The results suggested the drug helped in modulating the rats' desire to consume the ethanol or to enjoy its effects, the study said.

The scientists also found that, when the rats were later cut off from varenicline, they did not resume the intake of ethanol at previous levels.

"Chronic treatment with varenicline suppressed the ethanol consumption without any subsequent rebound increase in drinking," it said.

This finding "suggests that varenicline may serve as a therapeutic treatment to reduce alcohol consumption in alcoholic subjects."

The study was published in the newest edition of the Proceedings of the National Academy of Sciences.


'"/>




Page: 1

Related medicine news :

1. Anti-smoking advertisements to be funded by Cigarette manufacturers
2. FDA Approves Pfizer’s Anti-smoking Dru
3. Anti-smoking efforts bring down cancer death rates
4. Anti-smoking Programmes Should Increase
5. Anti-smoking Ads at the Movies Doesnt Make Any Impact on Smokers
6. Government to Toughen Its Anti-smoking Laws
7. Indian Government at the Crossroads in Implementing Anti-smoking
8. UAE Plans to Implement Anti-smoking Law
9. Tougher Tobacco Rules Urged at Global Anti-smoking Talks
10. Lean Protein Could Be Key to Obesity Drugs
11. Nasal Spray Could Take Drugs Direct to Brain.
Post Your Comments:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Pharmacy Technician Employment Increasing Up to 32% By 2016 2Antiabortion Advocate Appointed to Senior Position at HHS 48015 1Antiabortion Advocate Appointed to Senior Position at HHS 48015 2Special Ed Services Lacking for Kids Who Repeat a Grade 48011 1Special Ed Services Lacking for Kids Who Repeat a Grade 48011 2Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 1Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 2Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 3Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 4Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 5Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 6Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 7Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 8Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 9Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 10Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 11
Other Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6